{
  "extraction_metadata": {
    "timestamp": "2025-09-10T11:30:58.309387",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "total_picos": 35
  },
  "picos_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "a tumour localization that cannot be locally controlled or resected and with an ECOG status of 0 1 points",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sorafenib",
          "Outcomes": "overall survival, progression-free survival, response rates (measured by RECIST and mRECIST criteria, including complete response and partial response), adverse events and side-effects, intraoperative complications, mortality, morbidity, disease progression, time to deterioration, time to progression of the tumor, secondary resectability, quality of life, sustained virological response (for patients with HCV), tumour relapse (as detected by biomarkers), imaging-based assessment of tumour vascularisation and devascularizing effect, tumour control (reviewed after two treatment cycles), contraindications and treatment feasibility (based on ECOG status, Child-Pugh score, extrahepatic metastasis, portal vein thrombosis, and tumour vascularisation), efficacy of local and systemic therapies"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 6038
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab and bevacizumab",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "tremelimumab-durvalumab combination",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        },
        {
          "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": "health-related quality of life (measured by EORTC QLQ-30 and FACT-G, with disease-specific modules EORTC QLQ-HCC18 and FACT-Hep), survival, response rates, adverse events, symptom measurement and management, prognosis, early detection rate, liver function, general condition, complications of cirrhosis (including varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy grade >1 on New Haven criteria), resectability (reassessment after palliative oncological therapy), functional status (WHO PS 0-1, ECOG 0), portal hypertension and its management, decompensation (defined as occurrence of varicose vein bleeding, ascites, or hepatic encephalopathy), quality of treatment, patient safety"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 4290
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with (not locally treatable) HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab with bevacizumab",
          "Outcomes": "overall survival, progression-free survivorship (time from randomisation or initiation of treatment to progression or death, with a minimum follow-up of 1 year), response rate (tumour response rate), adverse events (grade ≥ 3), quality of life (overall quality of life measured with a validated and reliable instrument), local tumour control, success rate (downstaging/bridging), early detection of local recurrence or de novo tumor, physical and psychological complaints (distress, reported using a validated screening tool from diagnosis to treatment and follow-up)"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 5576
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "PICOs": [
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "arterial chemoembolization",
          "Outcomes": "partial response, objective response, survival, 2-year survival, 1-year survival, delay of recurrence, side effects of chemotherapeutic agents, complications of arterial embolization (including liver failure, pain, fever), serious complications, quality of life (not evaluated), antitumoral effect, virologic response (association with reduced risk for hepatocellular carcinoma in interferon studies), development of complications of cirrhosis, risk of needle tract seeding after biopsy or therapeutic intervention, prognosis determined by tumour stage, general health, liver function, and treatment efficacy"
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "radioactive Iodine 131 treatment",
          "Outcomes": "partial response, objective response, survival, 2-year survival, 1-year survival, delay of recurrence, side effects of chemotherapeutic agents, complications of arterial embolization (including liver failure, pain, fever), serious complications, quality of life (not evaluated), antitumoral effect, virologic response (association with reduced risk for hepatocellular carcinoma in interferon studies), development of complications of cirrhosis, risk of needle tract seeding after biopsy or therapeutic intervention, prognosis determined by tumour stage, general health, liver function, and treatment efficacy"
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "systemic chemotherapy (doxorubicin or cisplatin)",
          "Outcomes": "partial response, objective response, survival, 2-year survival, 1-year survival, delay of recurrence, side effects of chemotherapeutic agents, complications of arterial embolization (including liver failure, pain, fever), serious complications, quality of life (not evaluated), antitumoral effect, virologic response (association with reduced risk for hepatocellular carcinoma in interferon studies), development of complications of cirrhosis, risk of needle tract seeding after biopsy or therapeutic intervention, prognosis determined by tumour stage, general health, liver function, and treatment efficacy"
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "hormonal therapy with tamoxifen",
          "Outcomes": "partial response, objective response, survival, 2-year survival, 1-year survival, delay of recurrence, side effects of chemotherapeutic agents, complications of arterial embolization (including liver failure, pain, fever), serious complications, quality of life (not evaluated), antitumoral effect, virologic response (association with reduced risk for hepatocellular carcinoma in interferon studies), development of complications of cirrhosis, risk of needle tract seeding after biopsy or therapeutic intervention, prognosis determined by tumour stage, general health, liver function, and treatment efficacy"
        },
        {
          "Population": "patients with unresectable HCC",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "subcutaneous octreotide therapy",
          "Outcomes": "partial response, objective response, survival, 2-year survival, 1-year survival, delay of recurrence, side effects of chemotherapeutic agents, complications of arterial embolization (including liver failure, pain, fever), serious complications, quality of life (not evaluated), antitumoral effect, virologic response (association with reduced risk for hepatocellular carcinoma in interferon studies), development of complications of cirrhosis, risk of needle tract seeding after biopsy or therapeutic intervention, prognosis determined by tumour stage, general health, liver function, and treatment efficacy"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 5735
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "survival, prognosis (BCLC staging system), therapeutic efficacy, early detection of recurrences, identification of long-term treatment-related complications, adverse events, response rates (RECIST criteria), liver function assessment (Child–Pugh class, ALBI score), performance status (ECOG/PS), quality of life"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 5199
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "cirrhotic (max Child-Pugh B) patients with unresectable M0 multi-nodular HCC, in the absence of portal thrombosis",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "TACE",
          "Outcomes": "improved survival, response rates (RECIST criteria), adverse events (CTCAE v5.0), safety, long-term survival, cost-effectiveness, early diagnosis (measured by surveillance with upper abdominal ultrasound), risk of false positives in surveillance (with alpha-fetoprotein), liver-related morbidity, liver-related mortality, prognosis (assessed by Child-Pugh and MELD scores), rebleeding prophylaxis outcomes, down-staging prior to liver transplantation (intention-to-treat analysis), outcomes following liver transplantation (including Milan and UCSF criteria), outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection, safety and efficacy of radiotherapy, safety and efficacy of transarterial chemoembolization (TACE), safety and efficacy of drug-eluting bead TACE (TACE-DEB), safety and efficacy of percutaneous ablative treatments, safety and efficacy in patients with portal vein thrombosis, safety and efficacy in patients with Child-Pugh B liver cirrhosis, adverse events related to monitoring, cost-benefit ratio of surveillance"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 5999
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "patients with advanced hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "time-to-progression, toxicity, efficacy, safety, overall survival, response rates (RECIST criteria), adverse events (CTCAE v5.0), progression-free survival, quality of life, time to deterioration, tumor recurrence"
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "lenvatinib",
          "Outcomes": "time-to-progression, toxicity, efficacy, safety, overall survival, response rates (RECIST criteria), adverse events (CTCAE v5.0), progression-free survival, quality of life, time to deterioration, tumor recurrence"
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "atezolizumab plus bevacizumab",
          "Outcomes": "time-to-progression, toxicity, efficacy, safety, overall survival, response rates (RECIST criteria), adverse events (CTCAE v5.0), progression-free survival, quality of life, time to deterioration, tumor recurrence"
        },
        {
          "Population": "patients with unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "selective internal radiation therapy with yttrium-90 resin microspheres",
          "Outcomes": "time-to-progression, toxicity, efficacy, safety, overall survival, response rates (RECIST criteria), adverse events (CTCAE v5.0), progression-free survival, quality of life, time to deterioration, tumor recurrence"
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma previously treated with sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "nivolumab plus ipilimumab",
          "Outcomes": "time-to-progression, toxicity, efficacy, safety, overall survival, response rates (RECIST criteria), adverse events (CTCAE v5.0), progression-free survival, quality of life, time to deterioration, tumor recurrence"
        },
        {
          "Population": "patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations after sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucirumab",
          "Outcomes": "time-to-progression, toxicity, efficacy, safety, overall survival, response rates (RECIST criteria), adverse events (CTCAE v5.0), progression-free survival, quality of life, time to deterioration, tumor recurrence"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 7069
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "PICOs": [
        {
          "Population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "ramucyrumab",
          "Outcomes": "progression assessment incorporating tumour characteristics, liver function, and overall disease status; response to treatment measured by RECIST criteria (for locoregional therapies); response to treatment measured by mRECIST or RECIST systems (for systemic therapy); response assessment after resection, locoregional, or systemic therapy using multiphase computed tomography or magnetic resonance imaging with contrast; perioperative mortality; adverse events; completeness of ablation assessed by multiphase computed tomography with contrast immediately after procedure; follow-up for recurrence or residual disease after ablation using magnetic resonance imaging or multiphasic computed tomography at 4-6 weeks post-operation, then every 3 months for 1 year and every 6 months for 3 years; time to progression; undesirable effects on the development of hepatocellular carcinoma; bridging therapy and reduction of progression by locoregional methods; benefit from combination of loco-regional methods if one is not radical; overall survival"
        },
        {
          "Population": "patients who are well tolerant of sorafenib",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "regorafenib",
          "Outcomes": "progression assessment incorporating tumour characteristics, liver function, and overall disease status; response to treatment measured by RECIST criteria (for locoregional therapies); response to treatment measured by mRECIST or RECIST systems (for systemic therapy); response assessment after resection, locoregional, or systemic therapy using multiphase computed tomography or magnetic resonance imaging with contrast; perioperative mortality; adverse events; completeness of ablation assessed by multiphase computed tomography with contrast immediately after procedure; follow-up for recurrence or residual disease after ablation using magnetic resonance imaging or multiphasic computed tomography at 4-6 weeks post-operation, then every 3 months for 1 year and every 6 months for 3 years; time to progression; undesirable effects on the development of hepatocellular carcinoma; bridging therapy and reduction of progression by locoregional methods; benefit from combination of loco-regional methods if one is not radical; overall survival"
        },
        {
          "Population": "patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sorafenib",
          "Outcomes": "progression assessment incorporating tumour characteristics, liver function, and overall disease status; response to treatment measured by RECIST criteria (for locoregional therapies); response to treatment measured by mRECIST or RECIST systems (for systemic therapy); response assessment after resection, locoregional, or systemic therapy using multiphase computed tomography or magnetic resonance imaging with contrast; perioperative mortality; adverse events; completeness of ablation assessed by multiphase computed tomography with contrast immediately after procedure; follow-up for recurrence or residual disease after ablation using magnetic resonance imaging or multiphasic computed tomography at 4-6 weeks post-operation, then every 3 months for 1 year and every 6 months for 3 years; time to progression; undesirable effects on the development of hepatocellular carcinoma; bridging therapy and reduction of progression by locoregional methods; benefit from combination of loco-regional methods if one is not radical; overall survival"
        },
        {
          "Population": "patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "leninivat",
          "Outcomes": "progression assessment incorporating tumour characteristics, liver function, and overall disease status; response to treatment measured by RECIST criteria (for locoregional therapies); response to treatment measured by mRECIST or RECIST systems (for systemic therapy); response assessment after resection, locoregional, or systemic therapy using multiphase computed tomography or magnetic resonance imaging with contrast; perioperative mortality; adverse events; completeness of ablation assessed by multiphase computed tomography with contrast immediately after procedure; follow-up for recurrence or residual disease after ablation using magnetic resonance imaging or multiphasic computed tomography at 4-6 weeks post-operation, then every 3 months for 1 year and every 6 months for 3 years; time to progression; undesirable effects on the development of hepatocellular carcinoma; bridging therapy and reduction of progression by locoregional methods; benefit from combination of loco-regional methods if one is not radical; overall survival"
        },
        {
          "Population": "patients who have previously received bevacizumab with atezolizumab",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "cabozantinib",
          "Outcomes": "progression assessment incorporating tumour characteristics, liver function, and overall disease status; response to treatment measured by RECIST criteria (for locoregional therapies); response to treatment measured by mRECIST or RECIST systems (for systemic therapy); response assessment after resection, locoregional, or systemic therapy using multiphase computed tomography or magnetic resonance imaging with contrast; perioperative mortality; adverse events; completeness of ablation assessed by multiphase computed tomography with contrast immediately after procedure; follow-up for recurrence or residual disease after ablation using magnetic resonance imaging or multiphasic computed tomography at 4-6 weeks post-operation, then every 3 months for 1 year and every 6 months for 3 years; time to progression; undesirable effects on the development of hepatocellular carcinoma; bridging therapy and reduction of progression by locoregional methods; benefit from combination of loco-regional methods if one is not radical; overall survival"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 5406
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "therapy with Sorafenib may be offered for a tumour localization that cannot be locally controlled or resected and with an ECOG status of 0 1 points",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sorafenib",
          "Outcomes": "overall survival, progression-free survival, response rates (measured by mRECIST criteria: complete response, partial response), time to progression of the tumor, time to deterioration, adverse events (including intraoperative complications, neurotoxicity, and side-effects), secondary resectability, disease control (tumor control panel review after two treatment cycles), quality of life, risk of developing cardiomyopathy, risk of co-occurrence of EKG and coronary artery disease, mortality, morbidity"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 6038
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "survival, long-term survival, prognosis (assessed by tumour diameter and number of tumours), perioperative mortality, morbidity, risk of recurrence during the first 5 years after radical resection, serious complications (such as leukaemia, postoperative softening, gallbladder abscess), quality of life, local control rates (measured at 1 year after SBRT), diagnostic accuracy, adverse events"
        }
      ],
      "ChunksUsed": 24,
      "ContextTokens": 3818
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "mortality, adverse events (side-effects such as bleeding and tumour seeding following biopsy), diagnosis accuracy (using imaging-based criteria on CT, MRI, or contrast-enhanced US, and pathological examination), prognosis (assessed by panels of immunohistochemistry markers), detection of early hepatocellular carcinoma (by surveillance methods such as ultrasound and serum AFP measurement), false-positive results (from adding AFP to ultrasound), and differential diagnosis accuracy (distinguishing HCC from other liver tumours and benign nodules by pathology)"
        }
      ],
      "ChunksUsed": 22,
      "ContextTokens": 5548
    }
  }
}